Prognostic values of hematological biomarkers in locoregionally advanced nasopharyngeal carcinoma

孙健达; 张汉雄; 陈意标

doi:10.19401/j.cnki.1007-3639.2019.07.008

您当前的位置：

首页 >

文章列表页 >

Prognostic values of hematological biomarkers in locoregionally advanced nasopharyngeal carcinoma

更新时间：2026-01-27

- Prognostic values of hematological biomarkers in locoregionally advanced nasopharyngeal carcinoma
- China Oncology Vol. 29, Issue 7, Pages: 528-534(2019)
- 作者机构：
  
  广东省梅州市人民医院放疗科,广东,梅州,514031
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2019.07.008
  CLC： R739.63
- Published Online：12 July 2019，
  
  Published：12 July 2019
- 稿件说明：
移动端阅览
孙健达，熊俊，张汉雄，陈意标. 血液标志物在局部晚期鼻咽癌中的预测价值[J]. 中国癌症杂志, 2019, 29(7): 528-534.

孙健达, 张汉雄, 陈意标. Prognostic values of hematological biomarkers in locoregionally advanced nasopharyngeal carcinoma[J]. China Oncology, 2019, 29(7): 528-534.
孙健达，熊俊，张汉雄，陈意标. 血液标志物在局部晚期鼻咽癌中的预测价值[J]. 中国癌症杂志, 2019, 29(7): 528-534. DOI： 10.19401/j.cnki.1007-3639.2019.07.008.

孙健达, 张汉雄, 陈意标. Prognostic values of hematological biomarkers in locoregionally advanced nasopharyngeal carcinoma[J]. China Oncology, 2019, 29(7): 528-534. DOI： 10.19401/j.cnki.1007-3639.2019.07.008.

摘要

背景与目的：治疗前血液标志物在尼妥珠单抗治疗的局部晚期鼻咽癌患者中的预测作用目前尚未明确。探讨治疗前血液标志物与鼻咽癌分期之间的相关性，以及其在治疗后近期疗效的预测作用。方法：选择2015年5月—2018年10月收治的Ⅲ~Ⅳa期鼻咽癌患者共83例，所有患者均接受放化疗综合治疗，放疗过程中予以尼妥珠单抗治疗。治疗前检测患者的血小板计数、淋巴细胞计数、血小板与淋巴细胞比值（platelet to lymphocyte ratio，PLR）及EB病毒（Epstein-Barr virus，EBV）DNA拷贝数。结果：治疗前血小板计数、PLR及血浆EBV DNA水平均未显示出与鼻咽癌患者的T分期、N分期、临床分期及治疗后的肿瘤缓解程度存在显著的相关性。治疗前联合血小板计数和淋巴细胞计数与治疗后颈部淋巴结的缓解程度显著相关，血小板计数及淋巴细胞计数均正常的患者颈部淋巴结完全缓解率显著升高。结论：对于尼妥珠单抗治疗的局部晚期鼻咽癌，治疗前联合血小板计数和淋巴细胞计数较单独血小板计数、PLR和血浆EBV DNA水平更能预测患者的近期疗效。

Abstract

Background and purpose: The prognostic values of hematological biomarkers in locoregionally advanced nasopharyngeal carcinoma (NPC) patients treated with nimotuzumab remains unclear. This study investigated the association of pretreatment hematological biomarkers with staging

and its prognostic values for short-term efficacy after treatment. Methods: A total of 83 patients with stage Ⅲ or stage Ⅳa NPC were treated in Meizhou People’s Hospital from Apr. 2015 to Oct. 2018. All patients received chemoradiotherapy

and nimotuzumab was administered concurrently with radiotherapy. Platelet count

lymphocyte count

platelet to lymphocyte ratio (PLR) and Epstein-Barr virus (EBV) DNA were collected before treatment. Results: Pretreatment platelet count

PLR and EBV DNA levels were neither significantly associated with T stage

N stage and overall stage

nor the response extent of tumor after treatment. Pretreatment combination of platelet count and lymphocyte count showed significant correlation with the response rates of cervical lymph nodes after treatment. Complete response (CR) rates of cervical lymph nodes were significantly higher in patients without elevated platelet count and lymphocyte count. Conclusion: Pretreatment combination of platelet count and lymphocyte count

but not platelet count

PLR

or EBV DNA levels alone

could predict the short-term efficacy in locoregionally advanced NPC patients treated with nimotuzumab.

关键词

Keywords

references

Views

1993

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Risk of cancer therapy-related cardiotoxicity following the use of PD-1/PD-L1 inhibitors combined with chemoradiotherapy compared with chemoradiotherapy in solid tumors: a systematic review and Meta-analysis

Research status and progress of third-line treatment for metastatic colorectal cancer

Discovery and preliminary validation of five early gastric cancer biomarkers, including TAGLN2 and CTSD, based on serum proteomics

A comparative analysis of the long-term efficacy between partial hepatectomy and transcatheter arterial chemoembolization in patients with liver metastasis from nasopharyngeal carcinoma

Significant fundamental translational research on breast cancer in China: progress and prospects

Related Author

ZHENG Jinmei

WU Wanghui

ZHENG Jimei

LIU Ji

WU Fei

WANG Mingxuan

SU Qiang

Jingyu LIU

Related Institution

Department of Emergency, Beijing Friendship Hospital Capital Medical University

Zhangzhou Changtai District Hospital

Department of Pathology, School of Basic Medical Sciences of Fujian Medical University

Department of Oncology, Beijing Friendship Hospital Capital Medical University

Department of Oncology, The First Affiliated Hospital of Naval Medical University

AI问答

⁰